Migraine without aura. Migraine without aura [common migraine]
Conditions
Interventions
Intervention 1: Intervention:
The first group will be treated with Memantine (10 mg daily, orally) for 3 months. Intervention 2: Control:
In this group, patients will be treated with Sodium Valporate
Treatment - Drugs
Intervention:
The first group will be treated with Memantine (10 mg daily, orally) for 3 months.
Control:
In this group, patients will be treated with Sodium Valporate (Depakine), 500 mg per day, orally, for 3 months.
Sponsors
Vice Chancellor for research of Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria:Men and women diagnosed with migraine within an age range of 18-65 and the onset of disease before their 50s; The duration of migraine is at least 1 year; at least 6 attacks per month; at least 48 hours without headache between 2 attacks; no migraine prophylaxis until inclusion Exclusion criteria:Renal dysfunction; Having ICDH-II criteria for medication overuse headache; Taking antipsychotics or antidepressants in last 3 months; Drug or alcohol abuse; Allergic reactions to memantine and Its compounds; Resistance to all acute migraine medications; Pain disorders; severe psychiatric disorder; Severe infections; Malignancy; Low chance of survival; Severe cardiac and vascular diseases; Neurodegenerative diseases; Pregnancy and lactation; Women in childbearing age and sexually active are included in the study, only if they receive contraception; MIDAS greater than 18
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The average number of attacks in each month. Timepoint: 3 months of retrospective history taking before intervention, 1 month of prospective history taking before intervention, 3 months after onset of intervention. Method of measurement: Migraine diary. | — |
Secondary
| Measure | Time frame |
|---|---|
| Anxiety. Timepoint: at baseline,3 months after intervention. Method of measurement: Hospital anxiety and depression scale.;Number and type of medications used per attack. Timepoint: at baseline,3 months after intervention. Method of measurement: Migraine diary.;Functional disability. Timepoint: at baseline,3 months after intervention. Method of measurement: Migraine Disability Assessment (MIDAS).;Side effects. Timepoint: at baseline,3 months after intervention. Method of measurement: Migraine diary.;The mean pain intensity from 0-3 before taking analgesic. Timepoint: at baseline,3 months after intervention. Method of measurement: Migraine diary.;Average number of days with migraine headaches per month. Timepoint: at baseline,3 months after intervention. Method of measurement: Migraine diary.;Quality of life. Timepoint: at baseline,3 months after intervention. Method of measurement: SF-12.;Number of respondents. Timepoint: at baseline,3 months after intervention. Method of measurement: Migraine diary.;Depression. Timepoint: at baseline,3 months after intervention. Method of measurement: Hospital anxiety and depression scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAbbas Tafakhori
Tehran University of Medical Sciences
Outcome results
None listed